Invetech and AiCella Announce Strategic Collaboration to Advance Cell Therapy Innovation

USA - English

• APAC - English

SAN DIEGO, June 26, 2025 /PRNewswire/ -- Invetech, a global leader in solving complex manufacturing and product development challenges in the advanced therapies and diagnostics markets, today announced a strategic collaboration with AiCella, a company focused on harnessing the power of artificial intelligence (AI) to optimize the development of cell therapy production processes and maximize patient response to treatment. This partnership brings together Invetech's deep domain expertise in End-to-End custom automation with AiCella's cutting-edge artificial intelligence platform to deliver smarter, faster, and more cost-effective solutions for the industry - accelerating innovation and improving outcomes across the cell therapy landscape.

"This collaboration is about more than just combining technologies—it's about solving some of the most persistent challenges in cell therapy production," said Andreas Knaack, President of Invetech. "By integrating AiCella's predictive AI models with our proven technology platforms, we aim to help therapy developers identify critical process parameters earlier, reduce manufacturing variability, and ultimately accelerate the path to scalable, patient-ready therapies."

"Our goal at AiCella is to uncover the hidden relationships between process inputs and patient outcomes—insights that traditional methods often miss," said Geoffrey Stephens, PhD, CEO and Founder of AiCella. "Through this collaboration with Invetech, we're embedding our AI models directly into the development and manufacturing lifecycle. This allows us to not only optimize process performance but also to generate data-driven hypotheses about which parameters most influence therapeutic efficacy—bringing us closer to truly personalized, responsive cell therapies."

Invetech and AiCella will both be participating in upcoming industry events and webinars throughout 2025, including Meeting on the Mesa in October, where both companies will exhibit their joint capabilities.

For more information, visit https://www.invetechgroup.com and https://www.aicella.io.

About Invetech

Invetech is your trusted partner in solving complex End-to-End manufacturing and product development challenges in the global advanced therapies market. For more than three decades, we've partnered with leaders in diagnostics, life sciences, and cell therapy to co-create breakthrough solutions that transform ideas into market-ready technologies and therapies. Whether transitioning from early process development to commercial-scale manufacturing or optimizing complex workflows, our team combines scientific insight, engineering excellence and proven technology platforms to deliver tailored solutions. Our proven modules, technology platforms and custom automation solutions integrate seamlessly with your processes, reducing time to market, and supporting scalable, GMP-compliant manufacturing. Together with our clients, we're advancing healthcare.

About AiCella

AiCella is an AI-driven biotech startup transforming the $10B+ cell therapy manufacturing market. By integrating real-world process and clinical data with advanced machine learning models, AiCella's platform, Insights™, helps biopharma developers optimize manufacturing efficiency, reduce costs, and improve therapeutic outcomes. AiCella revolutionizes process development by seamlessly integrating real process and clinical data to maximize responses for patients. Using data collected with our world class, strategic partners, our Insights™ platform will enable researchers across the globe to bridge the gap between process development and clinical responses, unlocking unparalleled insights and accelerating the journey from innovation to impactful patient outcomes. Our dedication to leveraging unique datasets and groundbreaking technologies via the Insights™ platform drives us to shape the future of process development by empowering researchers to make unprecedented strides in improving human health.

Contacts:

Kelly Lord, Marketing Manager, Cell Therapy 
Invetech
[email protected]

Geoffrey Stephens, PhD, Founder & CEO
AiCella
[email protected]

SOURCE Invetech